Fluorescent Immunoassay Market Size, $3.77Bn by 2028, 5.6% CAGR Led by ELISA Segment (56.12% Market Share in 2021): The Insight Partners
The fluorescent immunoassay market size was valued at $2.57 billion in 2021 and is projected to reach $3.77 billion by 2028; it is expected to grow at a CAGR of 5.6% from 2021 to 2028.
/EIN News/ -- NEw York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Fluorescent Immunoassay Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (ELISA, Rapid Lateral Flow Immunoassay, and Others), Application (Infectious Diseases, Oncology, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Academic and Research Institutes, and Others)”, the global fluorescent immunoassay market growth is driven by the growing prevalence of chronic diseases and the increasing demand for cell therapies. However, the disadvantages of fluorescent immunoassays such as the limited analysis of proteins and certain large molecules present at relatively high concentrations and poor sensitivity hamper the market growth. The ELISA segment dominated the global immunoassay market and held the largest immunoassay market share of 56.12% in 2021. The infectious diseases segment dominated the global immunoassay market and held the largest immunoassay market share of 54.39% in 2021. The hospitals & clinics segment dominated the global immunoassay market and held the largest immunoassay market share of 43.16% in 2021.
The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis: https://www.theinsightpartners.com/sample/TIPRE00011093/
| Report Coverage | Details |
| Market Size Value in | US$ 2.57 Billion in 2021 |
| Market Size Value by | US$ 3.77 Billion by 2028 |
| Growth rate | CAGR of 5.6% from 2021 to 2028 |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
| No. of Pages | 194 |
| No. Tables | 81 |
| No. of Charts & Figures | 80 |
| Historical data available | Yes |
| Segments covered | Product Type, Application, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Global Fluorescent Immunoassay Market: Competition Landscape and Key Developments
Abbott, BD, bioMerieux SA, F. Hoffman-La Roche Ltd., Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Quidel Corp., Ortho Clinical Diagnostics Holdings plc, and Danaher are among the key companies operating in the global fluorescent immunoassay market. These companies commonly adopt product launches and expansion strategies to expand their footprint worldwide. They also broaden their respective product portfolios to meet the growing demand.
Schedule A Pre-Sale Discussion with The Author Team in A Slot That You Prefer to Address Queries on Scope of The Study, Customization, Introduction to Research Methodology, Assistance on Technologies and Market Definitions: https://www.theinsightpartners.com/inquiry/TIPRE00011093/
The global fluorescent immunoassay market players offer innovative products to meet consistent and evolving customer demands worldwide, which also permits them to maintain their brand name globally. A few of the recent developments in the global fluorescent immunoassay market are as follows:
In March 2022, Quidel Corporation acquired Ortho Clinical Diagnostics. The transaction is expected to close during the first half of the fiscal year 2022. The combined organization will unite the companies’ technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings.
In June 2021, Roche announced that it had launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of SARS-CoV-2 infections. The laboratory-based Elecsys SARS-CoV-2 Antigen test had earlier received a CE mark and has recently obtained the import license from CDSCO.
Fluorescence immunoassay is a sensitive technique that is used in the measurement of many compounds, including drugs, hormones, and proteins; in the identification of antibodies; and in the quantification of antigens such as viral particles and, potentially, bacteria. The fluorescence detection system includes higher sensitivity detection of the analyte, simplified reagents, and simpler assay designs. A modern fluorescent-based immunoassay uses a detection reagent or a fluorescent compound that absorbs light or energy (excitation energy) at a specific wavelength and then emits light or energy at a different wavelength.
Based on product type, the global fluorescent immunoassay market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA segment accounted for the largest market share in 2021 and is expected to grow at the highest CAGR during the forecast period. The large market share is attributed to the high use of immunoassay tests to diagnose cancer, infectious diseases, and other chronic complications.
Chronic diseases and conditions are on the rise worldwide. The need for costly chronic care is increasing, placing significant demands on healthcare systems. The rise in the aging population and changes in societal behavior contribute to a steady rise in these common and costly long-term health problems. The middle class is growing, and with the rise in urbanization, people are adopting a more sedentary lifestyle. This drives obesity rates and cases of diseases such as diabetes. According to the Centers for Disease Control and Prevention (CDC), an estimated 150 million Americans had one or more chronic conditions as of 2016. According to the World Health Organization (WHO), the prevalence of chronic diseases was projected to increase by 57% in 2020.
According to the National Center for Biotechnology Information (NCBI), chronic kidney disease (CKD) is the 14th leading cause of death worldwide and is responsible for 1.2 million deaths each year. The increasing incidence of CKD is primarily associated with lifestyle disorders such as hypertension, cardiovascular disease, hormonal imbalances, and diabetes. Early detection and treatment are crucial, as progressive CKD is associated with unfortunate clinical consequences, including end-stage kidney disease (ESKD), cardiovascular diseases, and increased mortality.
Have A 15-Minute-Long Discussion with The Lead Research Analyst and Author of The Report in A Time Slot Decided by You. You Will Be Briefed About the Contents of The Report and Queries Regarding the Scope of The Document Will Be Addressed as Well: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00011093
The diagnosis, prognosis, and control of chronic kidney disease are based on understanding the glomerular filtration rate (GFR). Cystatin-C is a better GFR marker than the commonly used creatinine. The fluorescence lateral flow immunoassay was developed and optimized to estimate the cystatin C value to calculate the glomerular filtration rate.
The COVID-19 pandemic highlighted the need for rapid and accurate nucleic acid detection at the point of care. Fluorescence-based quantitative reverse transcription PCR (RT-qPCR) has high sensitivity and specificity. In addition, a maximum of people infected with SARS-CoV-2 develop mild or no symptoms. There is, therefore, an urgent need to develop rapid, simple, and high-throughput assays for the detection of nucleic acids.
A standard fluorescence immunoassay system is a multiparametric, random access system that provides accurate and reliable diagnostic results. It is a system capable of performing qualitative and quantitative analyses of infections, respiratory diseases, and chronic diseases. A convenient user interface and laboratory information system (LIS)/ hospital information system (HIS) connectivity save valuable time, and ambiguous test results are a thing of the past as the analyzer automatically reads and interprets the results. A cut-off index provides a good reference point for medical decision-making. Therefore, there is a growing need for fluorescent immunoassays, owing to the rising number of chronic diseases worldwide.
Immediate Delivery of Our Off-The-Shelf Reports and Latest Research Studies, Through Flexible and Convenient Payment Methods: https://www.theinsightpartners.com/buy/TIPRE00011093/
Browse Adjoining Reports:
Immunoassay Market to 2027 - Global Analysis and Forecasts By Product (Reagents & Kits, Analyzers & Instruments, and Software & Services), Technology [Enzyme-Linked Immunosorbent Assays (ELISA), Fluorescence, Chemiluminescence, Rapid Test, Western Blot, Enzyme-Linked Immune Absorbent Spot (ELISPOT), and Polymerase Chain Reaction (PCR)], Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, and Others), and End User (Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, and Others)
Immunoassay Reagents and Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Reagents and kits, Analyzers); Platform (Chemiluminescence immunoassays, Fluorescence immunoassays, Enzyme immunoassay, Radioimmunoassays, Others); Technique (Enzyme-linked immunosorbent assays, Rapid tests, Enzyme-linked immunospot, Western blotting, Immuno-PCR, Other techniques); Specimen type (Saliva, Urine, Blood, Others); Application (Infectious diseases, Oncology and endocrinology, Hematology and blood screening, Autoimmune disorders, Toxicology, Other applications); End user (Hospitals, Clinical laboratories, Blood banks, Research and academic laboratories, Others) and Geography
Immuno Oncology Assays Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (Immunoassays, PCR, NGS, Flow Cytometry, Others); Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, Others); Application (Clinical Diagnostics, Research)
ELISA POT Assay kits Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (SLC15A1 ELISA POT assay kits, SLC15A2 ELISA POT assay kits, SLC15A4 ELISA POT assay kits, other ELISA POT Assay Kits); End User (Pharmaceutical and Biotech Companies, Independent Research Labs, Academic and Research Institutions)
Lateral Flow Assay Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product (Kits & Reagents, Lateral Flow Readers); Technique (Sandwich Assays, Multiplex Detection Assays, Competitive Assays); Application (Drug Development and Quality Testing, Clinical or Point-of-Care testing, Others); End User (Hospitals & Clinics, Home Care, Pharmaceutical & Biotechnology Companies) and Geography
Lateral Flow Immunoassays Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technique Type (Competitive Assay, Sandwich Assay, Multiplex Detection Assay); Application Type (Infectious Disease, Pregnancy and Fertility, Toxicology, Others); End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care, Others), Impact of covid-19 pandemic.
Lateral Flow Immunoassay Reader Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Digital or Mobile Readers, Benchtop Readers); End User (Hospitals and Clinics, Home Care, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Others)
Antinuclear Antibody Test Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Reagents and Assay Kits, Systems, Software, Services); Technique (Immunofluorescence, Elisa, Multiplex); Disease (Rheumatoid Arthritis, SLE, Scleroderma, Other Diseases); End User (Clinical Labs, Hospitals, Other)
Osteopontin ELISA Kit Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Human, Mouse, Rabbit, Dog, Others); Application (Hospital, Clinic, Diagnostic Laboratories, Others) and Geography
Native Bacterial and Viral Antigens Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Chlamydia Antigens, Adenovirus Antigens, Borrelia Antigens, Chikungunya Virus Antigens, Clostridium Antigens, and Dengue Virus Antigens), Pathogen Type (Inactivated Pathogen and Purified Pathogen); Application (ELISA, Immunoassay, SDS-PAGE, Hemagglutination, and Agglutination Test), End User (Diagnostic Laboratories and Centers, and Academic and Research Institutes), and Geography
IgM/IgG Antibody Rapid Test Kits Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (Lateral Flow, Agglutination, Solid Phase); End-User (Hospitals, Diagnostic Centers, Research Centers)
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/fluorescent-immunoassay-market
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
